David Parrot - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 3, 2026
David Parrot has filed 1 SEC Form 4 filing across 1 company in the last 90 days - buying. Lifetime open-market purchases: $40K.
Profile
David Parrot serves as Chief Financial Officer of Scribe Therapeutics, Inc. (SCTX). Parrot has reported 1 insider filing with the SEC since 2026. The most recent filing was in July 2026.
| Role | Chief Financial Officer |
|---|---|
| Notability | 34/100 |
Board memberships
- Scribe Therapeutics, Inc.
Reported roles
- Chief Financial Officer
Trading Pattern
InsiderAlpha's records for David Parrot go back to 2026: 1 primary Form 4 filing, an average of 1.0 per year. The typical open-market purchase is $20K (2 buys totaling $40K). The largest single buy on record is $20K of SCTX in 2026. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role David Parrot has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Chief Financial Officer at Scribe Therapeutics, Inc. (SCTX) - 1 filing, 2026
Recent Transactions
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-28 | SCTX | Scribe Therapeutics, Inc. | P - Open-market purchase | 1.3K | $15.00 | $20K |
| 2026-07-28 | SCTX | Scribe Therapeutics, Inc. | P - Open-market purchase | 1.3K | $15.00 | $20K |
Companies - Last 90 Days
- Scribe Therapeutics, Inc. (SCTX) - 1 filing, last 2026-07-28
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades at the companies David Parrot has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
- Behzad Aghazadeh - $36.26M of SCTX open-market activity in the last 12 months
- ORBIMED ADVISORS LLC - $15.00M of SCTX open-market activity in the last 12 months
- Carl L. Gordon - $15.00M of SCTX open-market activity in the last 12 months
- AH Bio Fund II, L.P. - $5.00M of SCTX open-market activity in the last 12 months
- Svetlana Lucas - $45K of SCTX open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- Charles A. Davis
- Deep Track Biotechnology Master Fund, Ltd.
- Robert E. Dixon
- Romeo R. Dizon
- Kevin Michael Donahue
- DONEGAL MUTUAL INSURANCE CO
- DORCHESTER MINERALS OPERATING LP
- Robert W. Duggan
Frequently Asked Questions
Who is David Parrot?
David Parrot serves as Chief Financial Officer of Scribe Therapeutics, Inc. (SCTX). Parrot has reported 1 insider filing with the SEC since 2026. The most recent filing was in July 2026.…
How many SEC Form 4 filings has David Parrot submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has David Parrot been buying or selling stock?
Recorded transactions: 2 open-market purchases ($40K) and 0 open-market sales across all tracked filings.
Where can I see all of David Parrot's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live David Parrot profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.